Background: Solid lipid nanoparticles (SLN) are colloidal drug carrier systems that contribute several
properties required from a sophisticated drug delivery system for increasing drug bioavailability and providing
effective therapy. Many advantages of SLN have been reported over traditional dosage forms and their colloidal
counterparts since the early 1990s. They were optimized for oral drug delivery for the first time. The first SLN
formulations were produced by reducing particle size of solid lipid microparticles by spray congealing technique
in the late 1980s. Then, studies have been continued investigating for their different administration routes else
including parenteral, transdermal, ocular, nasal, respiratory etc.
Methods: Their foremost qualifications such as their biocompatible nature and high drug entrapment efficiency
make them promising colloidal drug carrier systems for effective treatment of serious disasters like genetic
disorders and cancer.
Conclusion: In this review, therapeutic potential of drug delivery of SLN and nanostructured lipid carriers (NLC,
the second generation of SLN) are summarized considering researches and patents on their administration via
different routes and their preparations in the pharmaceutical market.